2.89
+0(+0.00%)
Currency In USD
Address
675 Arapeen Drive
Salt Lake City, UT 84108
United States of America
Phone
801 994 7383
Website
Sector
Healthcare
Industry
Biotechnology
Employees
16
First IPO Date
October 22, 2013
Name | Title | Pay | Year Born |
Dr. Mahesh V. Patel Ph.D. | Co-Founder, Interim Principal Financial Officer, Director, President & Chief Executive Officer | 669,168 | 1957 |
Ms. Krista Fogarty | Principal Accounting Officer & Corporate Controller | 307,050 | 1968 |
Dr. Nachiappan Chidambaram Ph.D. | Senior Vice President of Research & Development | 367,400 | 1969 |
Mr. Logan Morse | Vice President of Sales, Marketing & Operations | 413,580 | 1970 |
Dr. Anthony DelConte M. D., M.D. | Chief Medical Director | 0 | 1958 |
Lipocine Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of neuroendocrine and metabolic disorders. The company's primary development programs are based on oral delivery solutions for poorly bioavailable drugs. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1144, an oral prodrug of bioidentical testosterone that has completed Phase II clinical trial for the treatment of non-cirrhotic non-alcoholic steatohepatitis; LPCN 1111, an oral prodrug of testosterone tridecanoate for once daily dosing, which has completed Phase II clinical trial in hypogonadal men; LPCN 1148, a novel prodrug of testosterone and testosterone laurate for the management of decompensated cirrhosis; LPCN 1154, an investigational new drug application to conduct a Phase 2 study in Postpartum depression; LPCN 2101 for women with epilepsy, which has completed pre-clinical study; and LPCN 1107, an oral hydroxyprogesterone caproate product that has completed dose finding Phase II clinical trial for the prevention of recurrent preterm birth. The company is headquartered in Salt Lake City, Utah.